The pattern is particularly noticeable in people taking 7.5 mg or higher, where the absolute increase in peak concentration is more significant
Future research will determine whether GLP-1 drugs can become a mainstay in treating neurological and psychiatric conditions alongside traditional therapies
Consequently, the definition of treatment success is also expanding beyond headline weight loss achieved, to include the full spectrum of patients therapeutic needs, for example: Effective and durable weight maintenance Managing co-morbidities along the cardio-metabolic-renal spectrum Preserving muscle mass Tolerability, safety Convenience, e.g., delivered via oral therapies and/or less-frequent dosing * Including diabetes, ASCVD, Afib, HTN, PAH, dyslipidaemia, heart failure, PAD, MI, stroke, cardiovascular disease, CKD Source: IQVIA LAAD
Comment: Multiple commenters supported CMS' proposal to establish a transitional payment exception for CY 2026